Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:51 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Deferoxamine (DFO) Clear all

Conditions: Leptomeningeal Metastases
Interventions: Deferoxamine (DFO); Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Thalassemia, Iron Overload
Interventions: Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO); Drug
Lead sponsor: Elliott Vichinsky; Other
Eligibility: 8 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Oakland, California

Conditions: Diabetes Mellitus, Heart Disease, Hemochromatosis, Thalassemia
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 4 Years and older
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1985 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Beta-thalassemia, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis; Industry
Eligibility: 10 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois

Conditions: Thalassemia
Interventions: Deferoxamine, Deferasirox; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: New York, New York

Conditions: Myelodysplastic Syndrome, Iron Overload
Interventions: Deferasirox; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 42
States / cities: Birmingham, Alabama • Phoenix, Arizona • Concord, California + 36 more

Conditions: Intracerebral Hemorrhage
Interventions: Deferoxamine Mesylate, Placebo (for Deferoxamine Mesylate); Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 18 more

Conditions: Aneurysmal Subarachnoid Hemorrhage
Interventions: Deferoxamine, Placebo; Drug
Lead sponsor: Aditya S. Pandey, MD; Other
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Intracerebral Hemorrhage, ICH - Intracerebral Hemorrhage
Interventions: Minimally Invasive surgery (MIS), Deferoxamine, Standard Medical Care (SMD); Procedure · Drug · Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Transfusion-dependent Hemachromatosis, Thalassemia Major, Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, HIDA; Drug · Radiation
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stroke, Problem of Aging
Interventions: desferrioxamine; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Intracerebral Hemorrhage
Interventions: Deferoxamine Mesylate; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Glioma, Malignant Brain Neoplasm, Meningioma, Metastatic Malignant Neoplasm in the Brain
Interventions: Advanced Magnetic Resonance Imaging, Brain Surgery, Electronic Health Record Review, Immuno-Positron Emission Tomography Scan, Magnetic Resonance Imaging, Stereotactic Biopsy, Zirconium Zr 89 Crefmirlimab Berdoxam; Procedure · Other · Diagnostic Test
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Sickle Cell Disease
Interventions: Deferoxamine, Deferasirox, Deferiprone, Echocardiography, Electrocardiogram (ECG); Drug · Device
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Fairfax, Virginia • Falls Church, Virginia

Conditions: Sickle Cell Disease
Interventions: ICL670; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 31
States / cities: Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more

Conditions: Intracerebral Hemorrhage
Interventions: Deferoxamine, Normal saline; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 25
States / cities: Phoenix, Arizona • Palo Alto, California • San Francisco, California + 19 more

Conditions: Sickle Cell Disease, Iron Overload, Hemolytic Anemia
Interventions: Deferasirox (ICL670), Deferoxamine (DFO); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years and older
Enrollment: 212 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 56
States / cities: Birmingham, Alabama • Mobile, Alabama • Loma Linda, California + 32 more

Conditions: Cardiovascular Diseases, Heart Diseases, Beta-Thalassemia
Interventions: Deferoxamine, Deferiprone (L1); Drug
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years to 100 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 6
States / cities: Los Angeles, California • Oakland, California • Chicago, Illinois + 3 more

Conditions: Subarachnoid Hemorrhage
Interventions: desferrioxamine (DFO), placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: deferoxamine; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Chronic Cutaneous Ulcer, Sickle Cell Disease
Interventions: Deferoxamine Product, Placebo; Drug · Other
Lead sponsor: TauTona Group; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 4
States / cities: Birmingham, Alabama • Miami, Florida • Atlanta, Georgia + 1 more

Conditions: Metastatic Malignant Solid Neoplasm, Lymphoma
Interventions: Positron Emission Tomography, Stereotactic Body Radiation Therapy, Zirconium Zr 89-Df-Crefmirlimab, Intensity Modulated Radiation Therapy; Procedure · Radiation · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Duarte, California

Conditions: Iron Overload
Interventions: deferiprone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis

Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload

Deferoxamine for the Treatment of Hemochromatosis

Cardiac T2* in Beta-thalassemia Patients on Deferasirox Treatment

Iron Balance Study of Deferasirox, Deferoxamine and the Combination of Both

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Intracerebral Hemorrhage Deferoxamine Trial - iDEF Ttrial

Deferoxamine In the Treatment of Aneurysmal Subarachnoid Hemorrhage (aSAH)

Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

Pilot Study for Patients With Poor Response to Deferasirox

Modulation of Cerebral Blood Flow Using Iron Chelators

Dose Finding and Safety Study of Deferoxamine in Patients With Brain Hemorrhage

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

Early Screening and Treatment of Heart Complication in Sickle Cell Disease

Evaluation of the Safety, Tolerability, Pharmacokinetics (PK) and Effects on Liver Iron Concentration of ICL670 Relative to Deferoxamine(DFO).

High-Dose Deferoxamine in Intracerebral Hemorrhage

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Combination Therapy Compared With Single-Drug Therapy in Patients With Cardiac Diseases

Deferoxamine to Prevent Delayed Cerebral Ischemia After Subarachnoid Hemorrhage

Deferoxamine for Iron Overload Before Allogeneic Stem Cell Transplantation

Deferoxamine for Sickle Cell Chronic Leg Ulcer Treatment

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

Compassionate Use of Deferiprone for Patients With Thalassemia and Iron-Induced Heart Disease